BCEIA2023‖學術報告會大會報告1

BCEIA 2023預登記通道：http://t2.eainfor.com/T/p/103_6

　　語言：英文

　　時間：2023年9月6日

　　地點：學術會議區W201

　　邀請全球知名科學家介紹DNA存儲、納米毒理學等前沿科學技術，分享球差電鏡、微型化雙光子顯微鏡等高端儀器的研究進展，同時就質譜法和核磁共振法等研究生物大分子結構及功能、新型分離介質制備及蛋白藥物、疫苗純化等最新應用進行探討和展望。

Paul Westerhoff

教授, 美國亞利桑那州立大學

　　報告題目：Analytical Strategies to Assess PFAS Removal and Lifecycle Fate during Adsorption or Transformative Water Treatment Processes

　　報告摘要

　　Per -and polyfluoroalkyl substances (PFAS) occur in ground and surface water sources across the globe, and proposed drinking water regulations are driving PFAS treatment technology development and implementation. This presentation will first address current treatment technologies, which utilize adsorption (liquid to solid phase transformation), membranes (liquid to liquid separations) or transformative (oxidation or reduction) processes. Examples will be provided how treatment process efficiencies for “real waters” and how the processes challenge analytical methods. Second, the presentation addresses end-of-life for residuals (e.g., activated carbon) that contains PFAS, which will require incineration. Tracking PFAS during incineration requires unique analytical approaches to track fluorinated aqueous, gaseous and solid-phase species. Overall, the presentation will demonstrate how to match PFAS analytical strategies to PFAS drinking water treatment processes.

　　個人簡介

　　Dr. Paul Westerhoff is a Regents Professor and Fulton Chair of Environmental Engineering in the School of Sustainable Engineering and the Built Environment at Arizona State University. Since joining ASU he has held various administrative positions. After serving as the Civil and Environmental Engineering Department Chair he was the Founding Director for the School of Sustainable Engineering and the Built Environment, and served later as Associate & Vice Dean of Research in Engineering and ASU Vice Provost for Academic Programming. Dr. Westerhoff is the Deputy Director of a NSF ERC for Nanotechnology Enabled Water Treatment and co-Deputy Director of the NSF STC Science and Technologies for Phosphorus Sustainability Center. His research group addresses questions related to What pollutants exist in the environment? If they occur, do they matter? If they occur and matter, what do we do to address them? with a focus on pollutants in natural and engineered water systems. He has over 400 journal publications (H-index>100) and multiple patents. He is the recipient of the 2020 A.P. Black award, 2019 NWRI Clarke Prize, 2015 ASU Outstanding Doctoral Mentor, 2013 ARCADIS/AEESP Frontier in Research Award, and 2006 Paul L. Busch Award. He was elected to the National Academy of Engineering in 2023.

Paul Breitenbecher

CEO, Breiten Associates LLC

　　報告題目：False positive, negative, and unexpected Drug Testing Results in the Urine Toxicology Laboratory |藥物測試：尿液毒理學實驗室使用篩選法（免疫測定法）和確認法（MS）

　　報告摘要

　　In 1995 I co-authored a short article entitled “False-positive Immunoassay Results for Urine Benzodiazepine in Patients Receiving Oxaprozin (Daypro)”. This was published when rapid urine drug screening test methods were first becoming available. The laboratory community was starting to realize that not all assays can be tested for all of the thousands of drugs, substances or endogenous compounds that may potentially cause result errors.

　　There are false positive, false negative and unexpected patient urine drug test results that occur in the Urine Toxicology laboratory.

　　How does one research these results and assist the clinician in helping to assess these results to treat their patient?

　　Unexpected urine drug test results can occur during any phase of the testing process； however, the most common usual results occur during the pre -analytical or patient collection phase. During this phase patients can provide “fake” urine, take substances that can affect the testing method, or they can adulterate/dilute their urine specimen.

　　Depending on the screening test method used, the test method can be impacted by a variety of substances that can produce either false negative, false positive or usual results. Screening results can also be different than the confirmation results making interpretation of patient results even more confusing.

　　During this presentation we will review a basic screening test method and confirmation method. And discuss some of these unexpected urine drug test results.

　　個人簡介

　　Paul Breitenbecher在羅得島大學、康涅狄格大學、杜肯大學等高校進修了研究生課程，曾在哈佛先鋒醫學中心、諾華生物醫學研究院、病理實驗室公司（Inform Diagnostics，原名Miraca Life Sciences Inc.）等知名醫學機構和企業的實驗室從事管理工作。現任Breiten Associates LLC公司的首席執行官，為臨床實驗室和CRO領域的科研人員提供采購、咨詢等方面的技術支持。

Robert Wielgosz

國際計量局（BIPM）化學部主任

　　報告題目：Certified Reference Materials for a Global Greenhouse Gas Monitoring Infrastructure

　　報告摘要

　　Understanding sources and sinks of Greenhouse Gases (GHG) and the impact of policies to mitigate emissions provides a key tool for action against Climate Change. GHG emissions and uptake can be determined through measurement systems that include in situ measurement of GHG concentration at varying levels of spatial distribution. These measurements together with wind-speed measurements and numerical weather prediction and dispersion models can be used to determine spatially and time resolved GHG emissions and sinks. Maintaining a global system of such measurements, as envisaged, for example, by the WMO initiative on a coordinated global Greenhouse Gas Monitoring Infrastructure, requires close attention to quality assurance and equivalence of measurements from different sites. Significant emissions may lead to small changes in GHG concentration, requiring highly consistent calibration standards at different measurement sites. The presentation will cover the establishment and characterization of CO2 in air standards for the measurements of concentration as well as isotope ratio, for source apportionment, that are required in GHG measurement networks. Generating the highest precision measurements of CO2 in air requires adopting metrological traceability to defined sets of primary standards, the so-called scale approach. The conversion of CO2 in air amount fraction values from one scale to another requires the scale relationships to be well known, noting that the requirement for internal consistency of standards within a scale, such as the WMO-CO2-X2019 scale, is at the 0.01 μmol/mol level, and consistency between different scales should not exceed the 0.02 μmol/mol level [1]. Certified reference materials that are needed to calibrate both in-situ based optical/laser based GHG amount faction and isotope ratio measurements as well as mass spectrometric laboratory-based measurements of isotope ratio will be described, as well as on-going comparisons to verify their equivalence. These comparisons are supporting National

　　個人簡介

　　Robert Wielgosz博士是位于法國的國際計量局（BIPM）化學部的主任，其氣體計量實驗室負責組織空氣質量和溫室氣體標準國際比對。這些比對為由國家計量院（NMIs）和指定機構（DIs）組成的世全球大氣監測網絡提供標準支撐。他是國際計量委員會（CIPM）氣候變化和環境領域任務組成員，也是國際計量局-世界氣象組織（WMO）“氣候行動中的計量”研討會指導委員會主席。他發表測量科學相關論文60余篇，包括世界氣象組織大氣氣體成分測量指南。他擁有劍橋大學伊曼紐爾學院（英國）的自然科學碩士學位，巴斯大學（英國）的博士學位，并在烏爾姆大學（德國）完成了皇家學會歐洲交流研究。